For the year ending 2025-12-31, KALV made $49,078K in revenue. -$111,439K in net income. Net profit margin of -227.07%.
| Income Statement | 2025-12-31 | |||
|---|---|---|---|---|
| Product revenue, net | 49,078 | |||
| Cost of revenue | 3,081 | |||
| Research and development | 33,371 | |||
| Selling, general and administrative | 124,663 | |||
| Total operating expenses | 161,115 | |||
| Operating loss | -112,037 | |||
| Interest income | 5,789 | |||
| Interest expense | 12,895 | |||
| Foreign currency exchange gain | 30 | |||
| Other income, net | 8,556 | |||
| Total other income | 1,480 | |||
| Loss before income tax (benefit) expense | -110,557 | |||
| Income tax (benefit) expense | -1,033 | |||
| Net loss | -109,524 | |||
| Foreign currency translation loss | -1,004 | |||
| Unrealized holding gain on marketable securities | 316 | |||
| Reclassification adjustment for realized holding gain on marketable securities included in net loss | 1,227 | |||
| Total other comprehensive (loss) | -1,915 | |||
| Comprehensive loss | -111,439 | |||
| Basic EPS | -2.03 | |||
| Diluted EPS | -2.03 | |||
| Basic Average Shares | 53,870,007 | |||
| Diluted Average Shares | 53,870,007 | |||
KalVista Pharmaceuticals, Inc. (KALV)
KalVista Pharmaceuticals, Inc. (KALV)